Core Elements of Antibiotic Stewardship for Health Departments | Antibiotic Use | CDC
Respiratory Virus Toolkit
Prevalence of A baumannii and C auris in Patients Receiving Mechanical Ventilation
Ending the COVID-19 emergency and transitioning from emergency phase to longer-term disease management: guidance on calibrating the response, 4 September 2023
Bringing hope to communities: WHO installs new module clinic for primary health care in Kharkiv region
Recommended package of interventions for HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for people in prisons and other closed settings
Meeting report: Antimicrobial stewardship summit for selected Member States in the WHO African region
Characteristics of Medical Evacuation by Train in Ukraine, 2022
Candida auris: update to management guidance
Toward a deeper understanding of long COVID
Protective measures and options for public health response for avian influenza
Interim Guidance for Clinicians on Human Infections with Variant Flu
Guidelines for the clinical management of severe illness from influenza virus infections
Covid-19: Evusheld is unlikely to prevent infection with current or future variants, NICE concludes
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19
Lingering symptoms common after COVID hospitalization
Human monkeypox: diagnosis and management
International Pandemic Preparedness Secretariat Releases New Report; NAM President Victor Dzau Co-Chairs IPPS Scientific Advisory Group - National Academy of Medicine
Launch of global individual patient data platform for tuberculosis treatment
How Do I Screen for HIV? | Screening | Clinicians | HIV | CDC
COVID-19 Symptoms 6 Months After Onset and the Role of Vaccination for SARS-CoV-2 Infection
How are covid-19 symptoms changing?
Most long covid effects resolve within a year after mild infection | BMJ
Guide for clinicians evaluating an ill person for Ebola disease | Evaluating Patients | Clinicians | Ebola (Ebola Virus Disease) | CDC
Rapid recommendation: A living WHO guideline on drugs for covid-19
Clinical management of COVID-19: Living guideline, 13 January 2023
Therapeutics and COVID-19: Living guideline, 13 January 2023
Safety and monitoring for patients receiving Nirmatrelvir-ritonavir for COVID-19
Administration of Nirmatrelvir-ritonavir for COVID-19
Nirmatrelvir-ritonavir for COVID-19
Paxlovid reduces serious risks from Omicron variants
NIH funds eight studies to advance rapid diagnosis of COVID-19-related inflammatory syndrome in children
Mpox - Clinical Quick Reference
Mpox in the U.S.
Notes from the Field: Clinical and Epidemiologic Characteristics of Mpox Cases from the Initial Phase of the Outbreak — New York City, May 19–July 15, 2022 | MMWR
Epidemiologic and Clinical Features of Mpox in Transgender and Gender-Diverse Adults — United States, May–November 2022 | MMWR
Case management
Uganda Treats COVID-19 Patients in National Soccer Stadium | CDC
Covid-19: Molnupiravir does not cut hospital admissions or deaths in vaccinated people at high risk, trial finds
WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics Among Children and Adolescents Aged <18 Years Who Were Hospitalized or Died with Influenza — United States, 2021–22 Influenza Season
Evaluation of medicines to prevent COVID-19
Moving WHO guidance on antibiotics into the heart of clinical practice
Chikungunya fact sheet
Zika virus
The WHO Global Clinical Platform for Ebola virus disease
COVID-19 NMA Summary Report
Paxlovid Associated with Decreased COVID-19 Hospitalizations ..
Covid-19: "Grotesque inequity" that only a quarter of paxlovid courses go to poorer countries
Differences in COVID-19 Hospitalizations by Self-Reported Race and Ethnicity in a Hospital in Honolulu, Hawaii
Studies provide latest ‘real world' evidence on effectiveness of covid-19 treatments | BMJ
What You Should Know about Flu Antiviral Drugs
Covid-19: NICE rejects five treatments over uncertain evidence and price in draft guidance
COVID-19 Clinical Care Pathway
Covid-19: Evusheld protects the most vulnerable patients, analysis shows
Flu and acute respiratory illness (ARI) in prisons and other prescribed places of detention (PPDs)
Epidemiologic and Clinical Features of Children and Adolescents Aged <18 Years with Monkeypox — United States, May 17–September 24, 2022
Notes From the Field: Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code–Level Social Vulnerability — United States, December 23, 2021–August 28, 2022 | MMWR
Global tuberculosis report 2022
Guidance on Air Medical Transport (AMT) for Patients with Ebola Virus Disease (EVD) | Ebola Hemorrhagic Fever | CDC
Introduction to Nipah virus disease | OpenWHO
WHO announces the update of the Consolidated Guidelines on HIV Testing Services (update 2022–23)
4 things to know about COVID-19 treatment in the Pacific
Ocular Monkeypox — United States, July–September 2022 | MMWR
WHO-WIPO-WTO Workshop : Innovation and Access to diagnostics for COVID-19 and beyond
Monkeypox treatment trial begins in the Democratic Republic of the Congo | National Institutes of Health (NIH)
Solidarity clinical trial for COVID-19 treatments
Covid-19: Antiviral purchased by UK government does not lower risk of hospital admission, trial shows | The BMJ
Evusheld: Government is urged to expedite covid antibody treatment for vulnerable patients | The BMJ
Decision on Evusheld as a COVID-19 treatment - GOV.UK
Drug-resistant tuberculosis treatment | OpenWHO
Interim Clinical Considerations for Management of Ocular Monkeypox Virus Infection | Monkeypox | Poxvirus | CDC
Clinical Signs and Symptoms of Influenza | CDC
CDC - Malaria - Diagnosis & Treatment (United States) - Treatment (U.S.) - Guidelines for Clinicians
Therapeutics and COVID-19: Living guideline, 16 September 2022
WHO consolidated guidelines on tuberculosis: module 3: diagnosis: tests for TB infection
WHO operational handbook on tuberculosis: module 3: diagnosis: tests for tuberculosis infection
ACT-Accelerator Facilitation Council Working Group Report on Diagnostics and Therapeutics
No time for COVID-19 complacency, say key countries responsible for tracking global rollout of COVID-19 vaccines, tests and treatments
COVID-19 Test to Treat Guidelines for African Union Member States – Africa CDC
Monkeypox: NHS offers tecovirimat for severe or complicated cases | The BMJ
Children and Flu Antiviral Drugs | CDC
Clinical Considerations for Pain Management of Monkeypox | Monkeypox | Poxvirus | CDC
Patient's Guide to Monkeypox Treatment with TPOXX | Monkeypox | Poxvirus | CDC
Clinical management of COVID-19: Living guideline, 15 September 2022
WHO policy brief: COVID-19 testing, 14 September 2022
WHO policy brief: Clinical management of COVID-19, 14 September 2022
Two Cases of Monkeypox-Associated Encephalomyelitis — Colorado and the District of Columbia, July–August 2022 | MMWR
Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022 | MMWR
U.S. clinical trial evaluating antiviral for monkeypox begins | National Institutes of Health (NIH)
Antiviral Drugs for Seasonal Influenza: Additional Links and Resources | CDC
Multidrug-Resistant Strain of Salmonella Newport | Salmonella | CDC
A TB laboratory on wheels in Timor-Leste
WHO Target Product Profiles for Monkeypox Therapeutics
Antibody treatment protects adults against malaria | National Institutes of Health (NIH)
Demographics of Patients Receiving TPOXX for Treatment of Monkeypox | Monkeypox | Poxvirus | CDC
Report of a WHO expert consultation on dosing to enable implementation of treatment recommendations in the WHO consolidated guidelines on the management of TB in children and adolescents
Covid-19: Results from India's 12 molnupiravir clinical trials remain unpublished | The BMJ
WHO makes new recommendations for Ebola treatments, calls for improved access
Therapeutics for Ebola virus disease
Clinical characteristics of COVID-19
Covid-19: UK will not buy Evusheld owing to "insufficient data" on protection, government says | The BMJ
Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022 | MMWR
Epidemiologic and Clinical Characteristics of Monkeypox Cases — United States, May 17–July 22, 2022 | MMWR
Clinical management of COVID-19
Clinical Recognition | Monkeypox | Poxvirus | CDC
Monkeypox Living Evidence Profile - Canada.ca
Management of critical COVID-19 Advanced non-invasive respiratory support: high-flow nasal oxygen and non-invasive ventilation- Part 2
Management of critical COVID-19: Acute hypoxaemic respiratory failure and COVID-19
Preparation and administration of mAb114 for Ebola virus disease (EVD)
WHO publishes new guidelines on HIV, hepatitis and STIs for key populations
Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations
Monitoring HIV pre-exposure prophylaxis programmes in the EU/EEA
Clinical Considerations for Monkeypox in Children and Adolescents | Monkeypox | Poxvirus | CDC
Patient information for Paxlovid - GOV.UK
Report of the Commission on Human Medicines Expert Working Group on COVID-19 vaccine safety surveillance - GOV.UK
WHO recommends long-acting cabotegravir for HIV prevention
Guidelines on long-acting injectable cabotegravir for HIV prevention
Malaria chemoprevention efficacy study protocol
Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance
WHO launched new implementation guidance for simplified and differentiated service delivery of pre-exposure prophylaxis (PrEP)
Responding to the monkeypox outbreak: perspectives of clinicians treating patients with the disease
Clinical Considerations for Treatment and Prophylaxis of Monkeypox Virus Infection in People with HIV | Monkeypox | Poxvirus | CDC
Clinical Considerations for Monkeypox in People Who are Pregnant or Breastfeeding | Monkeypox | Poxvirus | CDC
Treatment Information for Healthcare Professionals | Monkeypox | Poxvirus | CDC
Clinician FAQs | Monkeypox | Poxvirus | CDC
Monitoring People Who Have Been Exposed | Monkeypox | Poxvirus | CDC
Interim Clinical Guidance for the Treatment of Monkeypox | Monkeypox | Poxvirus | CDC
Monkeypox - GOV.UK
WHO advises against use of two drugs for non-severe covid-19 | BMJ
Covid-19: Long covid risk is lower with omicron than delta, researchers find | The BMJ
NHS to rollout two new drugs to tackle superbugs | The BMJ
Covid-19: UK adds sore throat, headache, fatigue, and six other symptoms to official list | The BMJ
WHO Drug Information - Volume 36, No. 2
Tools and strategies for successful scale-up of TB preventive treatment
WHO preferred product characteristics for monoclonal antibodies for HIV prevention
The WHO Global Clinical Platform for COVID-19
Interferon treatment may reduce severity of COVID-19 in people with certain genetic factors | National Institutes of Health (NIH)
Therapeutics and COVID-19: living guideline
WHO announces updates on its guidance on tuberculosis care and support
WHO consolidated guidelines on tuberculosis: module 4: treatment: tuberculosis care and support
WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
HIV Diagnoses | HIV and Gay and Bisexual Men | HIV by Group | HIV/AIDS | CDC
Understanding and using WHO guidelines on tuberculosis | OpenWHO
Clinical management of COVID-19: Living guideline, 23 June 2022
Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code–Level Social Vulnerability — United States, December 23, 2021–May 21, 2022 | MMWR
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment — California, December 2021–May 2022 | MMWR
A New Drug Target against Malaria | Institut Pasteur
Global Clinical Platform
Highest-risk patients eligible for COVID-19 treatments: guide for patients - GOV.UK
COVID-19 Case Management Webinar Series: Care of the critical patient
WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia
Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report
Severity of disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection
Guidance for diagnostic testing of cases with severe acute hepatitis of unknown aetiology in children
Major improvements in quality of life for people with drug-susceptible TB expected following updates in TB treatment regimens
Clinical Guidance for Adenovirus Testing and Typing of Patients Under Investigation | CDC
Rapid communication: Key changes to the treatment of drug-resistant tuberculosis
The WHO Essential Medicines List Antibiotic Book: infographics
COVID-19 treatments - Canada.ca
Health Canada authorizes Evusheld for the prevention of COVID-19 in immune compromised adults and children - Canada.ca
WHO Operational Handbook on Tuberculosis, Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment
WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment
Clinical care of severe acute respiratory infections – Tool kit
Therapeutics and COVID-19
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022
Strengthening infection prevention and control and quality in health care for resilient health services: Tackling Deadly Diseases in Africa Programme (TDDAP):
Handbook for clinical management of dengue
WHO Global Initiative for Emergency and Essential Surgical Care (GIEESC)
WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator
Interim Guidance on the Use of Antiviral Medications for Treatment of Human Infections with Novel Influenza A Viruses Associated with Severe Human Disease | Avian Influenza (Flu)
Mitigating the COVID-19 outbreak through global data sharing
Good practices for selecting and procuring rapid diagnostic tests for malaria
COVID-19 respiratory equipment
Screening for Lead during the Domestic Medical Examination for Newly Arrived Refugees
Tuberculosis preventive treatment
Definitions and reporting framework for tuberculosis
WHO treatment guidelines for drug-resistant tuberculosis, 2016 update
Treatment and pharmaceutical prophylaxis of COVID-19
Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination
Self-Study Modules on Tuberculosis
WHO updates its treatment guidelines to include molnupiravir
Safety in administering medicines for neglected tropical diseases
Global Malaria Programme
Evusheld approved to prevent COVID-19 in people whose immune response is poor
Improving healthcare associated infection surveillance
Guidelines for prevention and control of Chikungunya fever
Haemophilus influenzae Disease (Including Hib)
Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region
World malaria report 2018
Clinical Considerations: Myocarditis and Pericarditis after Receipt of mRNA COVID-19 Vaccines Among Adolescents and Young Adults
WHO technical brief for countries preparing malaria funding requests for the Global Fund (2020–2022)
The South-East Asia Region Antimicrobial Stewardship 2022 Webinar Series
Covid-19: Evusheld is approved in UK for prophylaxis in immunocompromised people
The Global Health Observatory
